DSIP - delta sleep-inducing peptide - is a nine-amino-acid peptide with the sequence Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu.1
It was first isolated in 1977 by researchers in Basel, Switzerland, who identified it in the blood of rabbits placed in a sleep-like state and named it for the slow-wave ("delta") brain activity they associated with it.1
In the FDA's 2026 compounding
paperwork
it appears under the name Emideltide.
Despite decades of interest, the natural DSIP system remains poorly characterized - there is no single, clearly validated receptor or mechanism that explains its reported effects.1
DSIP is not an FDA-approved drug.
In plain English: DSIP is a small peptide first found in sleeping animals. Its name means "deep-sleep helper." In FDA papers it's called Emideltide.
What the research shows - and what it doesn't
DSIP actually has more human history than many gray-market peptides - but that history is old, small, and mixed. Studies in the 1980s explored it in insomnia, and some reported improved sleep.2
The most carefully designed trial, a 1992 double-blind study in chronic insomniacs, found only weak effects and concluded that short-term DSIP was "not likely to be of major therapeutic benefit."3
So the honest summary is: the human data exists but is dated, involves small numbers, and does not amount to the large, well-controlled trials that establish safety and effectiveness for insomnia, narcolepsy, or opioid withdrawal.23
Why DSIP still intrigues sleep researchers
DSIP has an almost mythic origin - isolated from the blood of sleeping animals - and a name that promises exactly what exhausted people want: deeper, delta-wave sleep. Small human studies decades ago hinted at benefit for stubborn insomnia and even withdrawal, and that rare thing among these peptides - actual human history - is what keeps it interesting.2
What keeps us honest is that the best-designed trial found
the
effect weak.3
How to read peptide research. Animal-study and cell-study findings describe what happened in a controlled experiment. They are a starting point for investigation, not evidence that a compound works - or is safe - in humans. Peppies does not claim any peptide treats, cures, or prevents any condition.
In plain English: Old, small human studies hinted it might help sleep, but the best-designed study found only a weak effect. The proof is thin.
Is DSIP legal in 2026?
Here is the direct answer as of July 2026:
It is not an FDA-approved drug. There is no approved DSIP product for any medical use.
It cannot be lawfully sold as a dietary supplement. The FDA treats unapproved injectable peptides marketed for human use as outside the lawful supplement framework.1
It currently has no cleared compounding pathway. DSIP was placed in "Category 2" of the FDA's interim list of bulk drug substances for pharmacy compounding under section 503A - the category for substances that raise significant safety concerns - and although the FDA removed it (with eleven other peptides) from Category 2 in April 2026 and referred it to the advisory committee, removal did not add it to the approved ("Category 1")
list.56
In plain terms, DSIP (Emideltide) sits in a regulatory gap: removed from the explicitly-restricted bucket, but not placed into any approved one.5
This section is educational and is not legal advice. Rules can vary and change; consult a qualified professional for your situation.
In plain English: It's not approved and has no legal made-to-order path yet.
The regulatory timeline
Sep 2023
FDA adds this and other peptides to Category 2 of the interim 503A bulks list, citing safety concerns such as limited human data.4
Apr 2026
FDA removes 12 peptides - including this one - from Category 2 and sets an advisory committee review.56
Jul 24, 2026 (Day 2)
The Pharmacy Compounding Advisory Committee meets to review seven peptides. The FDA-evaluated use here is opioid withdrawal, chronic insomnia, and narcolepsy.4
After the meeting
The committee's vote is advisory only. FDA then decides whether to begin formal rulemaking to add (or not add) this peptide to the 503A list. In its briefing materials, FDA staff proposed not adding the peptides under review.47
Where the public comes in
The July 23-24 advisory meeting has its own public docket (FDA-2025-N-6895), but that docket closes July 22, 2026, and the committee's vote is only a recommendation. The decision that actually determines access comes later, if and when the FDA opens a formal rulemaking. That is the public comment window that carries legal weight - and it is the moment Peppies is tracking.
Want to know the moment you can comment?
Join the list and we'll send a clear, step-by-step heads-up when the official public comment window opens - so your voice counts when it matters.
Is DSIP (Emideltide) legal in the United States in 2026?
DSIP is not an FDA-approved drug and has no cleared compounding pathway. It was in Category 2 of the interim 503A list, then removed in April 2026 and referred to the July 2026 advisory committee, where it is listed as 'Emideltide.' Removal did not place it on the approved list.456
Why is DSIP also called Emideltide?
'Emideltide' is the name used for the substance in the FDA's 2026 compounding review paperwork; it refers to the same delta sleep-inducing peptide.4
Does DSIP work for insomnia?
The evidence is old, small, and mixed. The best-designed human trial, in 1992, found only weak effects and concluded short-term DSIP was unlikely to be of major therapeutic benefit.3
Where to learn more
Want to dig into the primary science yourself? These are neutral, authoritative starting points - no sales pitch, just the record:
We link only to independent, authoritative sources - U.S. and international (NIH, FDA, Europe PMC/EMBL-EBI, and the EU/U.S. trial registries) - never to sellers.
U.S. Food and Drug Administration. "July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee." Agenda, evaluated uses, briefing materials, and docket FDA-2025-N-6895. fda.gov - PCAC July 2026 meetingwww.fda.gov
Federal Register. "Pharmacy Compounding Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments - Bulk Drug Substances Nominated for Inclusion on the Section 503A Bulk Drug Substances List." April 16, 2026. federalregister.govwww.federalregister.gov
Hyman, Phelps & McNamara. "FDA's Pep(tide) Rally: What Compounders and Industry Need to Know." FDA Law Blog, April 2026 (12 peptides removed from Category 2). thefdalawblog.comwww.thefdalawblog.com
